Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

US10966967B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Huji Turdi · Yardley, US
• Jon J. Hangeland · Levittown, US
• R. Michael Lawrence · Yardley, US
• Saleem Ahmad · Wall, US
• Wei Meng · Pennington, US
• Robert Paul Brigance · Levittown, US
• Pratik Devasthale · Plainsboro, US
• Guohua Zhao · Princeton, US

Key dates

• Filing date: May 21, 2020
• Grant date: Apr 6, 2021
• Expiry date: May 21, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/59
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.